Denali Therapeutics Inc. - 8-K Filing
Denali Therapeutics reported a first-quarter 2026 net loss of $128.4 million, down from $133.0 million in the same period in 2025. R&D expenses were $103.8 million, a decrease of $12.4 million, while G&A expenses rose to $33.5 million. The company holds $1.05 billion in cash and equivalents as of March 31, 2026. Key business updates include the FDA approval and U.S. launch of AVLAYAH for Hunter syndrome, the first patient dosed in the Phase 1b trial of DNL628 for Alzheimer’s, and the termination of the Takeda collaboration for DNL593. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $DNLI